Anika Therapeutics, Inc.
Anika Therapeutics, Inc. (Nasdaq: ANIK) develops and manufactures hyaluronic acid-based products for osteoarthritis pain management and orthopedic regenerative treatments. Its OA Pain Management portfolio includes Monovisc and Orthovisc, viscosupplement injections for osteoarthritis pain, and Cingal, a… From the company’s description.
Over the twelve months to Sep 30, 2026, Anika Therapeutics, Inc. reported revenue of $123.43M, up 52.5% from a year earlier, and a net loss of $1.77M. Its operating margin was −2.1%, and operations generated $7.48M in cash. In fiscal 2025, it reported revenue of $112.82M, down 5.9% from fiscal 2024, and a net loss of $10.88M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Anika Therapeutics, Inc. does
In the company’s own words
Anika Therapeutics, Inc. (Nasdaq: ANIK) develops and manufactures hyaluronic acid-based products for osteoarthritis pain management and orthopedic regenerative treatments. Its OA Pain Management portfolio includes Monovisc and Orthovisc, viscosupplement injections for osteoarthritis pain, and Cingal, a single-injection product combining hyaluronic acid with a fast-acting steroid. Its Regenerative Solutions portfolio includes Integrity, a scaffold for tendon repair; Hyalofast, a scaffold for cartilage regeneration; and Tactoset, an injectable bone substitute. Other products serve veterinary, surgical and ophthalmic applications. Customers include clinicians, surgeons, hospitals and ambulatory surgery centers; commercial partners and distributors market products in the United States and internationally. Johnson & Johnson MedTech markets Monovisc and Orthovisc in the United States, while Anika sells its regenerative products directly through its sales team and independent distributors. Founded in 1992, the company shifted its focus to its two core portfolios after selling Arthrosurface in 2024 and Parcus Medical in 2025. Anika reported research and development expenses of $25.8 million for fiscal 2025.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- BEDFORD, MA
- Fiscal year end
- December
- CIK
- 898437
- SIC
- 3841
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Anika Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Anika Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Anika Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Anika Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Anika Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”